JAK-STAT pathway in hematological malignancies: Achievements, challenges and future perspectives

Area of Science:

• Cell Biology
• Pathology
• Molecular Biology

Background:

• The Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway is a critical cellular communication system.
• This pathway regulates essential cellular processes including proliferation, differentiation, survival, and apoptosis.
• Dysregulation of JAK-STAT signaling is linked to immune disorders and cancer development, particularly hematologic malignancies.

Purpose of the Study:

• To provide a comprehensive overview of the JAK-STAT signaling pathway.
• To elucidate the role of JAK-STAT signaling in the pathogenesis of hematologic malignancies.
• To summarize current and emerging therapeutic strategies targeting the JAK-STAT pathway for hematologic malignancies.

Main Methods:

• Literature review of the JAK-STAT signaling pathway.
• Analysis of the relationship between JAK-STAT components and hematologic malignancies.
• Compilation of information on FDA-approved and preclinical drugs targeting the pathway.

Main Results:

• The JAK-STAT pathway's composition, activation, and regulation are detailed.
• The intricate connection between JAK-STAT signaling and hematologic malignancies is established.
• Current therapeutic landscape, including approved and investigational drugs, is presented.

Conclusions:

• Understanding JAK-STAT pathway regulation is vital for developing effective treatments for hematologic malignancies.
• Targeting the JAK-STAT pathway offers promising therapeutic avenues for blood cancers.
• Continued research is essential to address challenges and explore future directions in JAK-STAT-targeted therapies.